Critical Outcome T (OTCMKTS:COTQF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.

According to Zacks, “Critical Outcome Technologies Inc. is a biopharmaceutical company which focuses on treatment of cancer. The company’s product consists of COTI-2, a novel p53-dependent mechanism of action with selective and potent anti-cancer activity. Its artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds from disease specific drug discovery through chemical optimization and preclinical testing. Critical Outcome Technologies Inc. is based in London, Canada. “

Separately, ValuEngine lowered shares of Critical Outcome T from a “sell” rating to a “strong sell” rating in a research report on Thursday, October 5th.

Shares of Critical Outcome T (COTQF) traded down $0.09 during trading on Wednesday, reaching $0.80. 15,000 shares of the company’s stock were exchanged, compared to its average volume of 1,510. Critical Outcome T has a 1 year low of $0.80 and a 1 year high of $4.80.

COPYRIGHT VIOLATION NOTICE: “Critical Outcome T (COTQF) Rating Increased to Hold at Zacks Investment Research” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/12/06/critical-outcome-t-cotqf-rating-increased-to-hold-at-zacks-investment-research.html.

Critical Outcome T Company Profile

Critical Outcome Technologies Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer in Canada. The company’s proprietary artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds from disease specific drug discovery through chemical optimization and preclinical testing.

Receive News & Stock Ratings for Critical Outcome T Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Critical Outcome T and related stocks with our FREE daily email newsletter.